Linkedin
RLS logo_header
Linkedin

Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production

“Actinium-225 represents a transformative opportunity in the realm of cancer treatment. As we look ahead, the global demand for Ac-225 is poised to rise sharply, driven by the urgent need for innovative therapies that can target hard-to-reach tumors and metastases.” said Dr. Andrew Cavey, CEO, ITM and Actineer Board Chairman. “Actineer is leading the effort to deliver a stable and scalable supply of Ac-225 which is essential for advancing clinical trials and also for making life-saving treatments accessible to patients worldwide.”

Read the full story on "Actineer, a Joint Venture of ITM and CNL, Begins Actinium-225 Production"

Share:

More News

IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer

“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high

Vopimetostat and Daraxonrasib Demonstrated 92% ORR in Pancreatic Cancer

“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS

US FDA Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic NSCLC

“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung

Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome